GET DAILY SIGNALSPro-Dex (PDEX) Q1 Results Show 11% Sales Growth and Margin Expansion
Key Takeaways
- Net sales rose 11% year over year to $20.6 million, ahead of the roughly $20.40 million consensus estimate.
- Diluted earnings per share (EPS) came in at $0.92, well above the estimated $0.66, though below the prior-year quarter's $1.40.
- Gross margin expanded 4 percentage points to 33%, helped by a favorable product mix.
- Net income declined to $3.0 million from $4.7 million, reflecting sharply lower unrealized gains on marketable equity investments.
- Operating income grew 13% to $3.5 million even as operating expenses climbed 48%.
- For more information on PDEX, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- To discover additional market opportunities, explore Trending AI Robots.
Earnings Context and Why It Matters
Pro-Dex, Inc. (PDEX) designs, develops, and manufactures autoclavable, battery-powered and electric surgical drivers and shavers used primarily in orthopedic, thoracic, and maxocranial facial procedures. Its results matter to investors because the company is a contract manufacturer tied closely to a small number of medical device original equipment manufacturers (OEMs), including its largest customer. The first quarter of fiscal 2027, ended September 30, 2026, showed continued top-line momentum driven by next-generation handpiece shipments, offset by declining repair revenue from the legacy handpiece. With the recent acquisition of Advanced Precision Machining (APM) adding aerospace and defense machining capacity, this report offers an early look at how the expanded business is contributing to growth and margins. I also checked this using Tickeron’s AI Screener to see how PDEX compares to others in the industry.
Reported Results
For the fiscal 2027 first quarter, Pro-Dex reported net sales of $20.6 million, up $2.1 million, or 11%, from $18.5 million a year earlier and slightly above consensus estimates near $20.40 million. Diluted EPS was $0.92, exceeding the estimated $0.66 but down from $1.40 in the prior-year quarter.
Gross profit increased 28%, with gross margin expanding to 33% from 29%, driven by a favorable product mix. Operating income rose 13% to $3.5 million from $3.1 million. However, operating expenses increased 48% to $3.3 million, reflecting higher engineering and selling, general, and administrative costs, including APM's separate operations. From what I see, the margin improvement stands out as a positive signal for the core operations.
Net income declined to $3.0 million from $4.7 million. The year-ago quarter included $3.3 million in unrealized gains on marketable equity investments, versus only $73,000 this quarter — a volatile, non-operating factor that weighed on the comparison.
Market Reaction and Investor Sentiment
Pro-Dex shares have historically been responsive to earnings, and this report highlights a familiar theme: strong operational performance paired with noise from investment-related gains. The revenue beat and margin expansion support the core business story, while the year-over-year EPS decline reflects the absence of last year's large unrealized gains on the Monogram Technologies investment rather than an operating shortfall. Investor focus is likely to remain on the durability of next-generation handpiece demand, the ramp of APM's contribution, and whether operating expense growth moderates over coming quarters. I’m watching this closely as the operational trends develop.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching several factors tied to Pro-Dex's growth trajectory. Management indicated it expects to ship validation units in collaboration with Monogram and Zimmer Biomet later in fiscal 2027, a development that could signal future revenue opportunities for the next-generation handpiece program.
Margin trends will also be important. The 4-percentage-point gross margin improvement was encouraging, but a 48% jump in operating expenses shows the cost of integrating APM and scaling the organization. Whether gross margin gains can outpace rising engineering and administrative spending will be a key test of profitability over the next several quarters.
Finally, investors should monitor customer concentration risk. Much of Pro-Dex's revenue depends on a single large medical device customer, and the transition from legacy handpiece repairs to next-generation product shipments will continue to reshape the revenue mix. Broader demand in orthopedic surgical procedures, along with APM's aerospace and defense contribution, will help determine whether recent top-line momentum is sustained.
Using AI Tools in My Research Process
When reviewing earnings like these, I often turn to Tickeron’s AI Screener to quickly filter for comparable names in the medical device space and spot patterns in revenue growth or margin trends. The tool lets me apply technical and fundamental criteria across thousands of stocks, helping narrow focus without manual effort. It has become a regular part of how I cross-check ideas and identify potential peers or breakout candidates in the same sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PDEX's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for PDEX moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 29 of the 31 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on PDEX as a result. In 81 of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for PDEX just turned positive on October 27, 2026. Looking at past instances where PDEX's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
Following a +4.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDEX advanced for three days, in 242 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
PDEX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
PDEX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PDEX crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDEX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Aroon Indicator for PDEX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. PDEX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.143) is normal, around the industry mean (5.000). P/E Ratio (14.528) is within average values for comparable stocks, (37.535). Projected Growth (PEG Ratio) (0.400) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.061) is also within normal values, averaging (56.876).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of powered solutions
Industry PharmaceuticalsOther
Advertisement